Last reviewed · How we verify
ONC206
At a glance
| Generic name | ONC206 |
|---|---|
| Also known as | antagonist of dopamine receptor D2 (DRD2) /human mitochondrial caseinolytic protease P (ClpP)ClpP Agonist, DRD2 antagonist/ClpP agonist |
| Sponsor | Sabine Mueller, MD, PhD |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors (PHASE1)
- Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma (PHASE2)
- Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ONC206 CI brief — competitive landscape report
- ONC206 updates RSS · CI watch RSS
- Sabine Mueller, MD, PhD portfolio CI